Latest filings (excl ownership)
15-12G
Securities registration termination
17 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Apr 24
POSASR
Automatic shelf registration (post-effective amendment)
3 Apr 24
8-K
Completion of Acquisition or Disposition of Assets
3 Apr 24
SC 14D9/A
Tender offer solicitation (amended)
3 Apr 24
25-NSE
Exchange delisting
3 Apr 24
SC TO-T/A
Third party tender offer statement (amended)
3 Apr 24
SC 14D9/A
Tender offer solicitation (amended)
22 Mar 24
SC 14D9/A
Tender offer solicitation (amended)
19 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
19 Mar 24
SC 14D9
Tender offer solicitation
4 Mar 24
SC TO-T
Third party tender offer statement
4 Mar 24
SC14D9C
Written communication relating to third party tender offer
1 Mar 24
8-K
Entry into a Material Definitive Agreement
1 Mar 24
SC TO-C
Information about tender offer
27 Feb 24
SC14D9C
Written communication relating to third party tender offer
21 Feb 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
8-K
Regulation FD Disclosure
16 Jan 24
8-K
Departure of Directors or Certain Officers
22 Nov 23
8-K
Other Events
15 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
9 Nov 23
8-K
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
18 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
8 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
28 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
12 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Results of Operations and Financial Condition
17 Apr 23
S-8
Registration of securities for employees
17 Mar 23
10-K
2022 FY
Annual report
15 Mar 23
8-K
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
15 Mar 23
8-K
Other Events
21 Feb 23
8-K
Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
26 Jan 23
Latest ownership filings
4
James B. Tananbaum
5 Apr 24
4
Nima Farzan
5 Apr 24
4
DEAN J MITCHELL
5 Apr 24
4
Neha Krishnamohan
5 Apr 24
4
Alsup Laurie Smaldone
5 Apr 24
4
Melissa B, Epperly
5 Apr 24
4
Keith T. Flaherty
5 Apr 24
4
Helen Sabzevari
5 Apr 24
4
Michael E Rome
5 Apr 24
4
Jill DeSimone
5 Apr 24
4
Mark A Meltz
5 Apr 24
4
CARL L GORDON
5 Apr 24
4
Change in insider ownership
5 Apr 24
SC 13D/A
Foresite Capital Fund V, L.P.
5 Apr 24
4
Change in insider ownership
5 Apr 24
4
Neha Krishnamohan
5 Mar 24
4
Mark A Meltz
5 Mar 24
4
Richard Thomas Williams
5 Mar 24
SC 13D/A
Foresite Capital Fund V, L.P.
22 Feb 24
SC 13D/A
ORBIMED ADVISORS LLC
21 Feb 24
SC 13G/A
Nextech V Oncology S.C.S., SICAV-SIF
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Lynx1 Capital Management LP
14 Feb 24
4
Richard Thomas Williams
5 Dec 23
4
Neha Krishnamohan
5 Dec 23
4
Mark A Meltz
5 Dec 23
SC 13G
TANG CAPITAL PARTNERS LP
27 Nov 23
SC 13D/A
ORBIMED ADVISORS LLC
17 Nov 23
SC 13D/A
Foresite Capital Fund V, L.P.
17 Nov 23
SC 13D/A
ORBIMED ADVISORS LLC
14 Nov 23
SC 13D/A
Foresite Capital Fund V, L.P.
14 Nov 23
4
Neha Krishnamohan
6 Sep 23
4
Mark A Meltz
6 Sep 23
4
Richard Thomas Williams
6 Sep 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Aug 23
4
Helen Sabzevari
13 Jun 23
4
Alsup Laurie Smaldone
13 Jun 23
4
DEAN J MITCHELL
13 Jun 23
4
CARL L GORDON
13 Jun 23
4
Keith T. Flaherty
13 Jun 23